9 found
Order:
Disambiguations
Adriane Fugh-Berman [9]Adriane J. Fugh-Berman [1]
  1.  32
    Physicians Under the Influence: Social Psychology and Industry Marketing Strategies.Sunita Sah & Adriane Fugh-Berman - 2013 - Journal of Law, Medicine and Ethics 41 (3):665-672.
    Pharmaceutical and medical device companies apply social psychology to influence physicians' prescribing behavior and decision making. Physicians fail to recognize their vulnerability to commercial influences due to self-serving bias, rationalization, and cognitive dissonance. Professionalism offers little protection; even the most conscious and genuine commitment to ethical behavior cannot eliminate unintentional, subconscious bias. Six principles of influence — reciprocation, commitment, social proof, liking, authority, and scarcity — are key to the industry's routine marketing strategies, which rely on the illusion that the (...)
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark   18 citations  
  2.  25
    Physicians Under the Influence: Social Psychology and Industry Marketing Strategies.Sunita Sah & Adriane Fugh-Berman - 2013 - Journal of Law, Medicine and Ethics 41 (3):665-672.
    It is easier to resist at the beginning than at the end.– Leonardo da VinciPhysicians often believe that a conscious commitment to ethical behavior and professionalism will protect them from industry influence. Despite increasing concern over the extent of physician-industry relationships, physicians usually fail to recognize the nature and impact of subconscious and unintentional biases on therapeutic decision-making. Pharmaceutical and medical device companies, however, routinely demonstrate their knowledge of social psychology processes on behavior and apply these principles to their marketing. (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   18 citations  
  3.  8
    Should Medical Device Representatives Assist Surgeons?Fran Pollner, Bonnie O'Connor & Adriane Fugh-Berman - 2019 - Journal of Evaluation in Clinical Practice 25 (6):977-979.
    No categories
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  4.  8
    Pharmaceutical Ethics and Grassroots Activism in the United States: A Social History Perspective.Sharon Batt, Judy Butler, Olivia Shannon & Adriane Fugh-Berman - 2020 - Journal of Bioethical Inquiry 17 (1):49-60.
    Women’s health activists laid the groundwork for passage of the law that created the U.S. Food and Drug Administration in 1906. The pharmaceutical and food industries fought regulatory reforms then and continue to do so now. We examine public health activism in the Progressive Era, the postwar era and the present day. The women’s health movement began in the 1960s, and criticized both the pharmaceutical industry and the medical establishment. In the 1990s, patient advocacy groups began accepting industry funds; thousands (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  5.  16
    Hypoactive Sexual Desire Disorder: Inventing a Disease to Sell Low Libido.Antonie Meixel, Elena Yanchar & Adriane Fugh-Berman - 2015 - Journal of Medical Ethics 41 (10):859-862.
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  6.  19
    Gynecologists and Estrogen: An Affair of the Heart.Adriane Fugh-Berman & Anthony R. Scialli - 2006 - Perspectives in Biology and Medicine 49 (1):115-130.
  7.  14
    Carcinogenic Diagnosis.Adriane Fugh-Berman - 2006 - Hastings Center Report 36 (5):c3-c3.
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  8.  9
    CME Stands for Commercial Medical Education: And ACCME Still Won't Address the Issue.Adriane Fugh-Berman & Alycia Hogenmiller - 2016 - Journal of Medical Ethics 42 (3):172-173.
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  9. Ethics and Eplerenone.Shruti Gupta, Adriane J. Fugh-Berman & Anthony Scialli - 2013 - Journal of Medical Ethics 39 (2):110-114.
    The use of a placebo arm in clinical trials is unethical if there is an active comparator that is acceptably safe and effective. We argue that reasonable evidence of effectiveness and safety of an inexpensive alternative to an expensive therapy is sufficient to require that the inexpensive therapy be included as a comparator when the expensive therapy is tested, and that use of an inactive placebo comparator only is not ethical. For example, studies of the expensive drug eplerenone for congestive (...)
    Direct download (6 more)  
     
    Export citation  
     
    Bookmark